Will Herrington

Such a great @NatalieStaplin figure for SMART-C - should be on a #KidneyWk postcard we can buy (or on a souvenir fidget magnet!)

CKD and HF: Conclusions from a KDIGO Controversies Conference Unfortunately submitted before publication of presentation of DIGIT-HF and DECISION 😆 @JBauersachsMD kidney-international.org/article/S0085-…

📣SGLT2 inhibition for patients with ADPKD – closing the evidence gap 👉 an @erakidney e-seminar of the ERA Journal Club Speaker: @MuellerRom Moderator: @willkidney , Parminder Judge Panelist: Roslyn Simms

Error in NDT paper title IMO.😬The key conclusion from JAMA limits relevance to studied pts (ie, opposite of overgeneralisation). Worthy point is the limitation of available RCTs is lack of data on SGLT2i in pts with all of the 5x following: eGFR>45+uACR<200+no DM+no HF+no ASCVD!

Our latest video in our partnership with @DGlaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free: nej.md/DrG35

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY bit.ly/3WA9uoy #OpenAccess @grecombm @NatalieStaplin @Dilushiwijay @KillianDonovan @doreen_zhu @kayzieb77 @sarahngyoonai @KatherineTuttl8 @MartinLandray @ChristophWanne4 @shlipak_khrc @willkidney @Oxford_NDPH

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY bit.ly/3WA9uoy (OPEN ACCESS) @grecombm @NatalieStaplin @Dilushiwijay @KillianDonovan @doreen_zhu @kayzieb77 @sarahngyoonai @KatherineTuttl8 @MartinLandray @ChristophWanne4 @shlipak_khrc

💬 Editorial: #SGLT2 inhibitor treatment benefits extend to people with CKD and low albuminuria, as well as those with advanced #KidneyDisease, supporting wider use. ja.ma/4r2qv7Z

Meta-analysis: #SGLT2 inhibitors slow kidney decline consistently across CKD severity and albuminuria range, supporting their routine use for kidney health. ja.ma/3YK8cZ9

FDA is now open to Bayesian statistical approaches. A leap forward! Bayesian statistics can help: ✅ Clinical trial design ✅ Finding the optimal dose ✅ Extrapolation to children ✅ Leveraging phase 2 results in phase 3

🎉EASi-KIDNEY has recruited 3000 randomised participants! 📉EASi-KIDNEY will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD) ➡️buff.ly/qXd6j1S

18/ #NephJC EMPA individual-level meta by @willkidney , pooled data from >23,000 patients across four empagliflozin trials showed consistent reductions in AKI, CKD progression, and kidney failure across all subgroups PMID: 41082889 nephjc.com/news/2025/10/2…

@TheLancet starts the academic year with a landmark review on CKD with four global leaders @willkidney Parminder K Judge @meg21212 @ChristophWanne4 thelancet.com/journals/lance… @MarkusAtHome

#EASi-KIDNEY’s December logo🎄🎅 . ‘Tis the season to be jolly!! ⁦@Oxford_NDPH⁩

Fascinating Effects of Empagliflozin on UMOD in EMPA-KIDNEY - American Journal of Kidney Diseases - discussed ⁦@TwSocNephrolTSN⁩ yesterday #APCNxTSN25 ⁦@grecombm⁩ DPhil ajkd.org/article/S0272-…

Good idea for a tattoo!?!

2025 @thelancet.com #CKD seminar out! Read it for the latest evidence on how to manage what is projected to become a top 5 leading cause of death globally by 2050 (read it so in 25years’ time that does not happen…): sciencedirect.com/science/articl…

Important link to a @JAMA_current collaborative meta-analysis from #asn25 should you need to know more about the effects of #SGLT2i on kidney, CV, mortality & hospitalization outcomes in patients with and without diabetes, & at low levels of albuminuria: jamanetwork.com/journals/jama/…

A drop in Uromodulin might partly explain the nephroprotective effects of SGLT-2 I @grecombm @NatalieStaplin @willkidney @Oxford_NDPH @MarkusAtHome ajkd.org/article/S0272-…